ATE366309T1 - Caspasen-aktivatoren - Google Patents

Caspasen-aktivatoren

Info

Publication number
ATE366309T1
ATE366309T1 AT01900896T AT01900896T ATE366309T1 AT E366309 T1 ATE366309 T1 AT E366309T1 AT 01900896 T AT01900896 T AT 01900896T AT 01900896 T AT01900896 T AT 01900896T AT E366309 T1 ATE366309 T1 AT E366309T1
Authority
AT
Austria
Prior art keywords
activators
caspases
sequences
polypeptide
diagnostic
Prior art date
Application number
AT01900896T
Other languages
English (en)
Inventor
Xiaodong Wang
Chunying Du
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE366309T1 publication Critical patent/ATE366309T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AT01900896T 2000-01-06 2001-01-05 Caspasen-aktivatoren ATE366309T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/479,309 US6110691A (en) 2000-01-06 2000-01-06 Activators of caspases

Publications (1)

Publication Number Publication Date
ATE366309T1 true ATE366309T1 (de) 2007-07-15

Family

ID=23903477

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01900896T ATE366309T1 (de) 2000-01-06 2001-01-05 Caspasen-aktivatoren

Country Status (9)

Country Link
US (2) US6110691A (de)
EP (1) EP1244787B1 (de)
JP (1) JP3851819B2 (de)
AT (1) ATE366309T1 (de)
AU (1) AU2630701A (de)
CA (1) CA2395344C (de)
DE (1) DE60129202T2 (de)
ES (1) ES2288924T3 (de)
WO (1) WO2001049719A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166475B2 (en) * 1999-02-26 2007-01-23 Cyclacel Ltd. Compositions and methods for monitoring the modification state of a pair of polypeptides
WO2001016373A2 (en) * 1999-08-27 2001-03-08 Mitokor Assaying of mitochondrial intermembrane space protein translocation
US7163801B2 (en) * 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
AU2001286730A1 (en) * 2000-08-24 2002-03-04 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
AU2002244247B2 (en) 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
DE60221151T2 (de) * 2001-05-07 2008-03-20 The Burnham Institute, La Jolla Verfahren zur bestimmung der prognose von krebspatienten mittels tucan
JP2004531731A (ja) * 2001-05-31 2004-10-14 ザ トラスティーズ オブ プリンストン ユニバーシテイ Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ
US7361310B1 (en) * 2001-11-30 2008-04-22 Northwestern University Direct write nanolithographic deposition of nucleic acids from nanoscopic tips
EP1495124A2 (de) * 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptide zur verwendung als therapeutische mittel gegen krebs und autoimmunerkrankungen
EP1354952A1 (de) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-Peptide zur Verwendung als therapeutische Mittel gegen Krebs und Autoimmunerkrankungen
EP1354953A1 (de) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-Peptide zur Verwendung als therapeutische Mittel gegen Krebs und Autoimmunerkrankungen
US20040180828A1 (en) * 2003-01-30 2004-09-16 Yigong Shi Caspase-9 : BIR domain of XIAP complexes and methods of use
US20050233411A9 (en) * 2003-02-07 2005-10-20 Chunying Du Compositions and methods for cleaving IAP
US20080199439A1 (en) * 2003-02-12 2008-08-21 Mclendon George L IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
FR2857098B1 (fr) * 2003-07-04 2006-05-05 Inst Nat Sante Rech Med Procede de mise en evidence d'un evenement moleculaire dans une cellule grace a des proteines marqueurs fluorescentes.
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
US20060019335A1 (en) * 2004-07-20 2006-01-26 Chunying Du Compositions and methods to promote c-IAP autodegradation
US20080138847A1 (en) * 2004-09-23 2008-06-12 Yigong Shi Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
DK1851200T3 (da) 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
US20070049602A1 (en) 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP2009509128A (ja) * 2005-08-09 2009-03-05 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患の治療
RU2418807C2 (ru) * 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
SG10201407457UA (en) * 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CL2007002167A1 (es) * 2006-07-24 2009-01-23 Tetralogic Pharm Corp Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
AU2009261919A1 (en) * 2008-06-27 2009-12-30 Pharmascience Inc. Bridged secondary amines and use thereof as IAP BIR domain binding compounds
AU2010210403B2 (en) 2009-02-09 2016-07-28 The Board Of Trustees Of The University Of Illinois Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
US8916705B2 (en) 2011-10-14 2014-12-23 The Board of Trustees of The University of Illilnois Procaspase-activating compounds and compositions
US9592229B2 (en) 2012-03-02 2017-03-14 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
BR112014022123B1 (pt) 2012-03-06 2022-09-20 Vanquish Oncology, Inc. Uso de uma combinação para o tratamento de câncer
KR102074530B1 (ko) 2012-03-06 2020-02-06 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 조합 요법에 의한 프로카스파제 ３ 활성화
RU2578545C1 (ru) * 2015-01-12 2016-03-27 Федеральное государственное бюджетное научное учреждение "Восточно-Сибирский институт медико-экологических исследований" Способ оценки токсического действия наночастиц серебра, инкапсулированных в полимерную матрицу арабиногалактана, на ткань головного мозга лабораторных животных в отдаленном периоде воздействия
RU2621122C1 (ru) * 2016-04-25 2017-05-31 Федеральное государственное бюджетное научное учреждение "Восточно-Сибирский институт медико-экологических исследований" Способ оценки процесса апоптоза в ткани головного мозга лабораторных животных
IL274663B2 (en) 2017-11-17 2024-01-01 Univ Illinois Cancer therapy by degrading dual mek signaling
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1003856A1 (de) * 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, menschluches ced-4 homolog, ein aktivator von caspase-3
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides

Also Published As

Publication number Publication date
DE60129202T2 (de) 2008-03-06
EP1244787B1 (de) 2007-07-04
WO2001049719A3 (en) 2002-02-07
US6534267B1 (en) 2003-03-18
JP2003518943A (ja) 2003-06-17
EP1244787A2 (de) 2002-10-02
US6110691A (en) 2000-08-29
WO2001049719A2 (en) 2001-07-12
AU2630701A (en) 2001-07-16
CA2395344C (en) 2012-05-22
CA2395344A1 (en) 2001-07-12
DE60129202D1 (de) 2007-08-16
JP3851819B2 (ja) 2006-11-29
ES2288924T3 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
DE60129202D1 (de) Caspasen-aktivatoren
HUP0401124A2 (hu) VII koagulációs faktor származékok
DK1548032T3 (da) KDR-peptider og vacciner indeholdende disse
ATE466952T1 (de) Poly-zinkfinger-proteine mit verbesserten linkern
EP1767546A4 (de) Ein die angiogenese inhibierendes chimäres protein und dessen verwendung
YU21399A (sh) Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže
TR200003159T2 (tr) Antipicornaviral bileşikler, hazırlanışları ve kullanımları
TW200407425A (en) Human coagulation factor VII polypeptides
ATE425180T1 (de) Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
ATE397062T1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
EP1100815A4 (de) Von protease typ ii spaltbares peptid
ATE333520T1 (de) Neuartige polynukleotide und polypeptide des ifnalpha-21 gens
DK1352056T3 (da) Polypeptider, der er i stand til at fremkalde en immunreaktion mod cancer
DK1037916T3 (da) Erythrovirus og dets anvendelser
ATE334208T1 (de) Menschliche proteasen und für diese kodierende polynukleotide
DK1095143T3 (da) Inhibitor til diagnosticering og behandling af patienter med hæmofili A
TR200103240T2 (tr) Endoparazit öldürücü bileşimler.
ATE386109T1 (de) Neue menschliche hydroxylasen und diese codierende polynukleotide
ATE278011T1 (de) Human dnase ii
DE60141948D1 (de) Zur steuerung der parkinaktivität brauchbare zusammensetzungen
ATE309374T1 (de) Humane carboxypeptidasen und diese kodierende polynukleotide
ATE355378T1 (de) Menschliche phospholipasen und diese kodierende polynukleotide
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE366315T1 (de) Menschliche enzyme und dafür kodierende polynukleotide
ATE323162T1 (de) Menschliche neurexin-ähnliche proteine und dafür kodierende polynukleotide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties